论文部分内容阅读
据WHO统计,全球超过20亿人感染过乙型肝炎病毒(HBV),其中3.5亿成为慢性感染者,每年大约100万人死于HBV感染相关的慢性活动性肝炎、肝硬化和肝癌;我国是HBV感染的高发区,占总人口7.18%的人群感染HBV,每年死亡30万人〔1〕。自1967年作为“澳抗”被发现以来,乙型肝炎病毒表面抗原(HBsAg)一直作为HBV感染的定性标志物,但最近的技术进步已使得人们能够对HBsAg进行定量检测。研究表明,HBsAg定量可作为一种新的标志物而在乙型肝炎的诊断和管理中发挥重要作用。本文就HBsAg定量的检测技术及其临床意义做一总结。
According to WHO statistics, more than 2 billion people worldwide are infected with hepatitis B virus (HBV), of which 350 million are chronically infected. About 1 million people die each year of chronic active hepatitis, cirrhosis and liver cancer associated with HBV infection. Our country is High incidence of HBV infection, the population of 7.18% of the total population infected with HBV, 300,000 people die each year 〔1〕. Hepatitis B virus surface antigen (HBsAg) has been used as a qualitative marker of HBV infection since its discovery in 1967 as “Ao-Kang”, but recent technological advances have enabled the quantitative detection of HBsAg. Studies have shown that HBsAg quantification can be used as a new marker in the diagnosis and management of hepatitis B play an important role. This article summarizes the detection of HBsAg and its clinical significance.